Alopecia Areata
Alopecia areata is an autoimmune condition where the body's immune system attacks its own hair follicles, causing sudden, unpredictable patches of hair loss.
Emergency Management: There are no medical emergencies directly related to alopecia areata, though acute psychological crises regarding self-image may require urgent psychiatric support.
A chronic, non-scarring, autoimmune hair loss disorder characterized by the sudden onset of sharply defined patches of hair loss. The core pathology involves a T-cell mediated inflammatory attack on the hair follicle bulbs, prematurely forcing them into the resting (telogen) phase.
Detailed Overview
Alopecia areata is highly unpredictable. It typically presents as round, smooth patches of total hair loss on the scalp or beard, without any scaling or inflammation visible on the skin surface. The disease can remain localized, progress to total loss of scalp hair (Alopecia Totalis), or result in the loss of all body hair (Alopecia Universalis). While the hair follicles are attacked, their stem cells are not destroyed, meaning hair regrowth is always possible, even after years of disease. Psychological impact is profound.
Epidemiology & Demographics
Lifetime risk is approximately 2% in the general population. Occurs at any age, but onset is most common before age 30. Equal incidence in males and females. Affects all ethnicities equally.
Etiological Mechanism
Considered a polygenic autoimmune disease triggered by environmental factors. It is mediated by cytotoxic CD8+ T-cells targeting autoantigens in the anagen-phase hair follicle, collapsing the follicle's immune privilege.
Primary Causes
Autoimmune attack of the hair follicle
Genetic predisposition (HLA class II alleles)
Severe acute emotional or physical stress (potential trigger)
Viral infections (potential trigger)
Normal anagen (growing) hair follicles reside in an 'immune-privileged' environment, devoid of MHC class I expression. In alopecia areata, stress signals (like IFN-gamma) induce ectopic expression of MHC class I and II on the follicular epithelium. Autoreactive CD8+ NKG2D+ T-cells recognize follicular autoantigens and release pro-inflammatory cytokines (IFN-gamma, IL-15). This inflammatory swarm (peribulbar lymphocytic infiltrate or 'swarm of bees') arrests hair synthesis, forces the follicle into early catagen, and sheds the hair shaft. Because the bulge region containing follicular stem cells is spared, permanent scarring does not occur.
Diagnostic Criteria & Guidelines
Clinical diagnosis based on the classic appearance of non-scarring patchy hair loss and exclamation mark hairs on dermoscopy. Scalp biopsy (showing peribulbar lymphocytic infiltrates) is rarely needed unless diagnosis is in doubt.
Intralesional Corticosteroids (Triamcinolone acetonide 2.5-10 mg/mL injected subcutaneously every 4-6 weeks) for limited patchy disease. Topical potent corticosteroids (Clobetasol 0.05% ointment daily) can be used as an adjunct or in children.
Second-Line & Adjunctive Therapy
For extensive disease (Totalis/Universalis): Oral JAK inhibitors (Baricitinib 2-4 mg daily or Ritlecitinib 50 mg daily). Alternative: Topical immunotherapy (DPCP or SADBE) to induce a localized allergic contact dermatitis that distracts the immune system.
Surgical & Procedural Management
Hair transplantation is contraindicated and ineffective, as the immune system will attack the transplanted follicles.
Patient Counseling & Advice
Reassure the patient that their overall physical health is not in danger and that the hair follicles remain alive, meaning hair can regrow at any time. However, be honest about the unpredictable nature of the disease: spontaneous remission is common in patchy disease, but relapses are frequent, and extensive disease is harder to treat.
Follow-Up & Monitoring Schedule
Monitor treatment response every 6-8 weeks. Monitor for side effects of intralesional steroids (skin atrophy, hypopigmentation). For patients on JAK inhibitors, monitor CBC, lipid panels, and liver function tests regularly.
Preventive Strategies
No known preventative measures. Stress management techniques may be helpful, though stress is a trigger rather than the root cause.
Highly variable. 50% of patients with mild patchy disease experience spontaneous regrowth within 1 year without treatment. However, 10-20% progress to Totalis or Universalis, where spontaneous recovery is rare (<10%). Poor prognostic factors include onset in childhood, presence of nail disease, and concurrent atopy.